Strategic collaborations

Our collaboration strategy is a key element in executing our corporate strategy. We are committed to developing transformational therapies that address high unmet needs in oncology and immune-oncology. We strive to be a partner of choice and enter collaborations and strategic partnerships with leading biopharma companies to further broaden our oncology pipeline, to advance our clinical-stage programs following clinical proof-of-concept, so we eventually commercialize differentiated therapies that matter to oncology patients.


We are committed to the identification, in-licensing and systematic development of promising therapeutic candidates. Via in-licensing initiatives, we are eager to evaluate therapeutic frontiers in late-preclinical and clinical stages of development with an emphasis on ...

View In-Licensing


We seek to collaborate with leading global pharmaceutical and biopharma companies with a proven track record in clinical development, for completion of the final phases of the clinical trials after clinical proof-of-concept, and commercial capabilities, ...

View Out-Licensing